The research compound in Contrave®
Contrave® is a weight management medicine from Currax Pharmaceuticals. Its active compound is Naltrexone/Bupropion — which is what this catalogue supplies, as a research material.
This is not Contrave®, and NOVALYTE LABS has no affiliation with Currax Pharmaceuticals. We supply the compound Naltrexone/Bupropion for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Contrave® is a trademark of Currax Pharmaceuticals, referenced here only to identify the compound.
Contrave is the United States brand for the naltrexone and bupropion combination, marketed as Mysimba in Europe.
The two agents act on central pathways rather than on gut hormones, which places it outside the GLP-1 class entirely.
The combination is listed here as a research material with batch documentation.
Naltrexone/Bupropion in this catalogue
100mg oral tablets
How Naltrexone/Bupropion is supplied here
Everything below describes the research material in this catalogue, not the medicine.
| Compound | Naltrexone/Bupropion |
|---|---|
| Presentation | 100mg oral tablets |
| Dosage options | 100mg |
| Research category | Metabolic Research |
| Batch COA | Certificate supplied with order |
| Availability | In stock |
| Intended use | Laboratory research only — not for human or veterinary use |
Common questions
What is the active compound in Contrave?
Naltrexone/Bupropion. Contrave is a registered trademark of Currax Pharmaceuticals, approved for weight management.
Is this Contrave?
No. NOVALYTE LABS supplies Naltrexone/Bupropion as a research material with batch documentation. It is not Contrave, it is not a medicine, it is not supplied for human use, and there is no affiliation with Currax Pharmaceuticals.
Why is Naltrexone/Bupropion sold under more than one brand?
Because a brand is tied to an approved indication rather than to the molecule. Naltrexone/Bupropion is marketed as Contrave and also as Mysimba — same compound, different approvals.
Other brands using Naltrexone/Bupropion
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.